BACKGROUND AND PURPOSE: The cannabinoid receptor-mediated analgesic effects of 2-arachidonoylglycerol (2-AG) are limited by monoacylglycerol lipase (MAGL). 4-nitrophenyl 4-[bis (1,3-benzodioxol-5-yl) (hydroxy) methyl] piperidine-1-carboxylate (JZL184) is a potent inhibitor of MAGL in the mouse, though potency is reportedly reduced in the rat. Here we have assessed the effects of spinal inhibition of MAGL with JZL184 on nociceptive processing in rats. EXPERIMENTAL APPROACH: In vivo spinal electrophysiological assays in anaesthetized rats were used to determine the effects of spinal administration of JZL184 on spinal nociceptive processing in the presence and absence of hindpaw inflammation. Contributions of CB(1) receptors to these effects was assessed with AM251. Inhibition of 2-oleoylglycerol hydrolytic activity and alterations of 2-AG in the spinal cord after JZL 184 were also assessed. KEY RESULTS: Spinal JZL184 dose-dependently inhibited mechanically evoked responses of wide dynamic range (WDR) neurones in naïve anaesthetized rats, in part via the CB(1) receptor. A single spinal administration of JZL184 abolished inflammation-induced expansion of the receptive fields of spinal WDR neurones. However, neither spinal nor systemic JZL184 altered levels of 2-AG, or 2-oleoylglycerol hydrolytic activity in the spinal cord, although JZL184 displayed robust inhibition of MAGL when incubated with spinal cord tissue in vitro. CONCLUSIONS AND IMPLICATIONS: JZL184 exerted robust anti-nociceptive effects at the level of the spinal cord in vivo and inhibited rat spinal cord MAGL activity in vitro. The discordance between in vivo and in vitro assays suggests that localized sites of action of JZL184 produce these profound functional inhibitory effects. LINKED ARTICLES: This article is part of a themed section on Cannabinoids. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.167.issue-8.
BACKGROUND AND PURPOSE: The cannabinoid receptor-mediated analgesic effects of 2-arachidonoylglycerol (2-AG) are limited by monoacylglycerol lipase (MAGL). 4-nitrophenyl 4-[bis (1,3-benzodioxol-5-yl) (hydroxy) methyl] piperidine-1-carboxylate (JZL184) is a potent inhibitor of MAGL in the mouse, though potency is reportedly reduced in the rat. Here we have assessed the effects of spinal inhibition of MAGL with JZL184 on nociceptive processing in rats. EXPERIMENTAL APPROACH: In vivo spinal electrophysiological assays in anaesthetized rats were used to determine the effects of spinal administration of JZL184 on spinal nociceptive processing in the presence and absence of hindpaw inflammation. Contributions of CB(1) receptors to these effects was assessed with AM251. Inhibition of 2-oleoylglycerol hydrolytic activity and alterations of 2-AG in the spinal cord after JZL 184 were also assessed. KEY RESULTS: Spinal JZL184 dose-dependently inhibited mechanically evoked responses of wide dynamic range (WDR) neurones in naïve anaesthetized rats, in part via the CB(1) receptor. A single spinal administration of JZL184 abolished inflammation-induced expansion of the receptive fields of spinal WDR neurones. However, neither spinal nor systemic JZL184 altered levels of 2-AG, or 2-oleoylglycerol hydrolytic activity in the spinal cord, although JZL184 displayed robust inhibition of MAGL when incubated with spinal cord tissue in vitro. CONCLUSIONS AND IMPLICATIONS: JZL184 exerted robust anti-nociceptive effects at the level of the spinal cord in vivo and inhibited rat spinal cord MAGL activity in vitro. The discordance between in vivo and in vitro assays suggests that localized sites of action of JZL184 produce these profound functional inhibitory effects. LINKED ARTICLES: This article is part of a themed section on Cannabinoids. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.167.issue-8.
Authors: Steven J R Elmes; Maulik D Jhaveri; Darren Smart; David A Kendall; Victoria Chapman Journal: Eur J Neurosci Date: 2004-11 Impact factor: 3.386
Authors: Daniel K Nomura; Bradley E Morrison; Jacqueline L Blankman; Jonathan Z Long; Steven G Kinsey; Maria Cecilia G Marcondes; Anna M Ward; Yun Kyung Hahn; Aron H Lichtman; Bruno Conti; Benjamin F Cravatt Journal: Science Date: 2011-10-20 Impact factor: 47.728
Authors: Richard L Suplita; Tannia Gutierrez; Darren Fegley; Daniele Piomelli; Andrea G Hohmann Journal: Neuropharmacology Date: 2005-11-28 Impact factor: 5.250
Authors: Devi Rani Sagar; Lydia E Staniaszek; Bright N Okine; Stephen Woodhams; Leonie M Norris; Richard G Pearson; Michael J Garle; Stephen P H Alexander; Andrew J Bennett; David A Barrett; David A Kendall; Brigitte E Scammell; Victoria Chapman Journal: Arthritis Rheum Date: 2010-12
Authors: John D Douglass; Yin Xiu Zhou; Amy Wu; John A Zadroga; Angela M Gajda; Atreju I Lackey; Wensheng Lang; Kristen M Chevalier; Steven W Sutton; Sui-Po Zhang; Christopher M Flores; Margery A Connelly; Judith Storch Journal: J Lipid Res Date: 2015-04-04 Impact factor: 5.922
Authors: Stephen G Woodhams; Victoria Chapman; David P Finn; Andrea G Hohmann; Volker Neugebauer Journal: Neuropharmacology Date: 2017-06-15 Impact factor: 5.250
Authors: Robert A Owens; Bogna Ignatowska-Jankowska; Mohammed Mustafa; Patrick M Beardsley; Jenny L Wiley; Abdulmajeed Jali; Dana E Selley; Micah J Niphakis; Benjamin F Cravatt; Aron H Lichtman Journal: J Pharmacol Exp Ther Date: 2016-06-15 Impact factor: 4.030
Authors: B M Ignatowska-Jankowska; S Ghosh; M S Crowe; S G Kinsey; M J Niphakis; R A Abdullah; Q Tao; S T O' Neal; D M Walentiny; J L Wiley; B F Cravatt; A H Lichtman Journal: Br J Pharmacol Date: 2014-03 Impact factor: 8.739